| Galia Regina Abadi, MD | |
|
1646 Elmira Street, Aurora, CO 80010 | |
| (303) 315-7424 | |
| Not Available |
| Full Name | Galia Regina Abadi |
|---|---|
| Gender | Female |
| Speciality | Psychiatry |
| Experience | 17 Years |
| Location | 1646 Elmira Street, Aurora, Colorado |
| Accepts Medicare Assignments | May be. She may accept the Medicare-approved amount; you may be billed for more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1407051378 | NPI | - | NPPES |
| 12345527 | Other | CO | CAQH |
| 45939870 | Medicaid | CO |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084P0800X | Psychiatry & Neurology - Psychiatry | DR.0048957 (Colorado) | Primary |
| Entity Name | Galia R Abadi Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1154941540 PECOS PAC ID: 4385065093 Enrollment ID: O20200605000142 |
News Archive
On an ice hockey team, the players all start off with identical uniforms, skates and a stick. But if you take one of them, add padding, a glove, and a mask; and switch the stick to one with a larger blade, then you get a goalie.
Hospital care providers need to be more aware that cardiac arrest from a medication-induced heart rhythm problem is a rare but potentially catastrophic event in patients, according to a joint scientific statement from the American Heart Association and American College of Cardiology.
Kaiser Foundation Hospitals, Kaiser Foundation Health Plan, Inc., and their respective subsidiaries reported today a combined total operating revenue of $14.0 billion for the quarter ending June 30, 2014, compared to $13.3 billion in the same period in 2013.
The Alzheimer's Drug Discovery Foundation announces a $2.1 million grant awarded to R. Scott Turner, MD, PhD, of Georgetown University Medical Center to conduct a phase II clinical trial of low-dose nilotinib (marketed as Tasigna for use as a cancer therapy) in patients with Alzheimer's disease.
Today, Boehringer Ingelheim has announced the submission of a Marketing Authorisation Application to the European Medicines Agency (EMA) for approval of afatinib, the first irreversible ErbB Family Blocker, as a treatment for patients with EGFR (ErbB1) mutation positive non-small cell lung cancer (NSCLC). Afatinib has demonstrated unprecedented efficacy versus chemotherapy in the Phase III LUX-Lung 3 registration trial, which provides pivotal support for this submission.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Galia Regina Abadi, MD 11059 E. Bethany Drive, Aurora, CO 80014 Ph: (303) 345-4770 | Galia Regina Abadi, MD 1646 Elmira Street, Aurora, CO 80010 Ph: (303) 315-7424 |
News Archive
On an ice hockey team, the players all start off with identical uniforms, skates and a stick. But if you take one of them, add padding, a glove, and a mask; and switch the stick to one with a larger blade, then you get a goalie.
Hospital care providers need to be more aware that cardiac arrest from a medication-induced heart rhythm problem is a rare but potentially catastrophic event in patients, according to a joint scientific statement from the American Heart Association and American College of Cardiology.
Kaiser Foundation Hospitals, Kaiser Foundation Health Plan, Inc., and their respective subsidiaries reported today a combined total operating revenue of $14.0 billion for the quarter ending June 30, 2014, compared to $13.3 billion in the same period in 2013.
The Alzheimer's Drug Discovery Foundation announces a $2.1 million grant awarded to R. Scott Turner, MD, PhD, of Georgetown University Medical Center to conduct a phase II clinical trial of low-dose nilotinib (marketed as Tasigna for use as a cancer therapy) in patients with Alzheimer's disease.
Today, Boehringer Ingelheim has announced the submission of a Marketing Authorisation Application to the European Medicines Agency (EMA) for approval of afatinib, the first irreversible ErbB Family Blocker, as a treatment for patients with EGFR (ErbB1) mutation positive non-small cell lung cancer (NSCLC). Afatinib has demonstrated unprecedented efficacy versus chemotherapy in the Phase III LUX-Lung 3 registration trial, which provides pivotal support for this submission.
› Verified 3 days ago
Lea C Watson, MD Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 1890 N Revere Ct, Aurora, CO 80045 Phone: 720-848-0000 | |
Robert House, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 12605 E 16th Ave, Aurora, CO 80045 Phone: 720-848-0000 | |
Ann Olincy, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 12605 E 16th Ave, Aurora, CO 80045 Phone: 720-848-0000 | |
Paul Moe, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 13123 E 16th Ave, Aurora, CO 80045 Phone: 720-777-1234 | |
Dr. Erin Schwarz, D.O. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 1537 Alton St, Aurora, CO 80010 Phone: 303-617-2300 | |
Robert Clyman, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 13123 E 16th Ave, Aurora, CO 80045 Phone: 720-777-1234 | |
Dr. Bishara Bhasi, MD Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 13123 E 16th Ave, Aurora, CO 80045 Phone: 720-848-0000 |